Posted by Michael Wonder on 22 Aug 2022
CSL Vifor and Travere Therapeutics announce EMA has accepted for review the conditional marketing authorisation application for sparsentan for the treatment of IgA nephropathy
22 August 2022 - A review decision by the EMA is expected in the second half of 2023.
CSL Vifor and Travere Therapeutics today announced that the EMA has accepted for review the conditional marketing authorisation application for sparsentan for the treatment of IgAN, a rare kidney disorder and a leading cause of end stage kidney disease.
